National Pension Service Buys 260,853 Shares of Boston Scientific Corporation $BSX

Key Points

• National Pension Service increased its Boston Scientific stake by 7.1%, buying 260,853 additional shares to hold 3.96 million shares valued at approximately $169 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific shares opened at $43.03, down 4.3%, despite the company beating quarterly earnings and revenue expectations. Revenue rose 7.5% year over year, while management issued third-quarter and full-year 2026 earnings guidance.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $71.46, and the company authorized a $5 billion share-repurchase program. Directors also recently bought shares, adding to recent insider purchases.

National Pension Service increased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 7.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,959,598 shares of the medical equipment provider's stock after acquiring an additional 260,853 shares during the quarter. National Pension Service owned about 0.27% of Boston Scientific worth $168,996,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. CYBER HORNET ETFs LLC increased its stake in shares of Boston Scientific by 3.4% in the third quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider's stock worth $391,000 after purchasing an additional 132 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management lifted its stake in shares of Boston Scientific by 4.7% during the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider's stock valued at $294,000 after buying an additional 139 shares in the last quarter. Northwestern Mutual Investment Management Company LLC lifted its stake in shares of Boston Scientific by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider's stock valued at $4,516,000 after buying an additional 140 shares in the last quarter. Kingsview Wealth Management LLC increased its stake in Boston Scientific by 2.4% in the 4th quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider's stock worth $578,000 after buying an additional 142 shares in the last quarter. Finally, RiverFront Investment Group LLC increased its stake in Boston Scientific by 0.7% in the 4th quarter. RiverFront Investment Group LLC now owns 21,308 shares of the medical equipment provider's stock worth $2,032,000 after buying an additional 150 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Trading Down 4.3%

Shares of Boston Scientific stock opened at $43.03 on Friday. The firm has a market cap of $62.36 billion, a price-to-earnings ratio of 17.42, a PEG ratio of 1.04 and a beta of 0.57. The business has a 50-day moving average price of $47.04 and a 200-day moving average price of $54.74. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $105.72.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the business earned $0.75 earnings per share. The firm's revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has authorized a share repurchase program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on BSX shares. Wolfe Research downgraded Boston Scientific from an "outperform" rating to a "peer perform" rating in a research report on Friday, May 29th. Oppenheimer cut their target price on Boston Scientific from $90.00 to $85.00 and set an "outperform" rating for the company in a research report on Monday, July 27th. Truist Financial decreased their target price on Boston Scientific from $62.00 to $57.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $60.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Finally, Wells Fargo & Company cut their price objective on shares of Boston Scientific from $55.00 to $50.00 and set an "equal weight" rating for the company in a report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $71.46.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig bought 5,000 shares of the business's stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger purchased 2,100 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares of the company's stock, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 194,522 shares of company stock valued at $9,385,210 in the last ninety days. Corporate insiders own 0.34% of the company's stock.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.